{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:43:36Z","timestamp":1791942216279,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00520-022-06956-0","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T06:08:36Z","timestamp":1647324516000},"page":"5339-5349","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A retrospective study on chemotherapy-induced nausea and vomiting in highly\/moderately emetogenic chemotherapy: incidence and prescribing practice"],"prefix":"10.1007","volume":"30","author":[{"given":"Nurul Suhaida","family":"Badarudin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2509-4213","authenticated-orcid":false,"given":"Noraida","family":"Mohamed Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamarun Neasa Begam","family":"Mohd Kassim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuad","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farida","family":"Islahudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurul Ain","family":"Mohd Tahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhana","family":"Yusak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"key":"6956_CR1","doi-asserted-by":"crossref","unstructured":"de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer. 1997;76(8):1055\u201361.","DOI":"10.1038\/bjc.1997.507"},{"issue":"4","key":"6956_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00520-004-0710-6","volume":"13","author":"CC Sun","year":"2005","unstructured":"Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW et al (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13(4):219\u2013227","journal-title":"Support Care Cancer"},{"issue":"2","key":"6956_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00520-006-0109-7","volume":"15","author":"E Ballatori","year":"2007","unstructured":"Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S, Soru G et al (2007) The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer 15(2):179\u2013185","journal-title":"Support Care Cancer"},{"issue":"5","key":"6956_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00520-006-0173-z","volume":"15","author":"L Cohen","year":"2007","unstructured":"Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15(5):497\u2013503","journal-title":"Support Care Cancer"},{"issue":"1","key":"6956_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00520-009-0797-x","volume":"19","author":"TA Burke","year":"2011","unstructured":"Burke TA, Wisniewski T, Ernst FR (2011) Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer 19(1):131\u2013140","journal-title":"Support Care Cancer"},{"issue":"3","key":"6956_CR6","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/cncr.22823","volume":"110","author":"YC Tina Shih","year":"2007","unstructured":"Tina Shih YC, Xu Y, Elting LS (2007) Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 110(3):678\u2013685","journal-title":"Cancer"},{"issue":"1","key":"6956_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00520-018-4464-y","volume":"27","author":"Y Razvi","year":"2019","unstructured":"Razvi Y, Chan S, McFarlane T, McKenzie E, Zaki P, DeAngelis C et al (2019) ASCO, NCCN, MASCC\/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer 27(1):87\u201395","journal-title":"Support Care Cancer"},{"issue":"Suppl 1","key":"6956_CR8","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1007\/s00520-010-1003-x","volume":"19","author":"SM Grunberg","year":"2011","unstructured":"Grunberg SM, Warr D, Gralla RJ, Rapoport BL, Hesketh PJ, Jordan K et al (2011) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity\u2013state of the art. Support Care Cancer 19(Suppl 1):S43\u2013S47","journal-title":"Support Care Cancer"},{"key":"6956_CR9","first-page":"19","volume":"8","author":"BL Rapoport","year":"2017","unstructured":"Rapoport BL (2017) Delayed chemotherapy-induced nausea and vomiting: pathogenesis, incidence, and current management. Front Pharmacol 8:19","journal-title":"Front Pharmacol"},{"issue":"1","key":"6956_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1200\/JCO.1997.15.1.103","volume":"15","author":"PJ Hesketh","year":"1997","unstructured":"Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15(1):103\u2013109","journal-title":"J Clin Oncol"},{"issue":"1","key":"6956_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00520-014-2373-2","volume":"23","author":"RK Hsieh","year":"2015","unstructured":"Hsieh RK, Chan A, Kim HK, Yu S, Kim JG, Lee MA et al (2015) Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Support Care Cancer 23(1):263\u2013272","journal-title":"Support Care Cancer"},{"issue":"11","key":"6956_CR12","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s00520-015-2801-y","volume":"23","author":"C Hernandez Torres","year":"2015","unstructured":"Hernandez Torres C, Mazzarello S, Ng T, Dranitsaris G, Hutton B, Smith S et al (2015) Defining optimal control of chemotherapy-induced nausea and vomiting-based on patients\u2019 experience. Support Care Cancer 23(11):3341\u20133359","journal-title":"Support Care Cancer"},{"issue":"8","key":"6956_CR13","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1093\/annonc\/mds021","volume":"23","author":"M Aapro","year":"2012","unstructured":"Aapro M, Molassiotis A, Dicato M, Pel\u00e1ez I, Rodr\u00edguez-Lescure \u00c1, Pastorelli D et al (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23(8):1986\u20131992","journal-title":"Ann Oncol"},{"issue":"6","key":"6956_CR14","first-page":"1523","volume":"11","author":"BA Hassan","year":"2010","unstructured":"Hassan BA, Yusoff ZB (2010) Negative impact of chemotherapy on breast cancer patients QOL - utility of antiemetic treatment guidelines and the role of race. Asian Pac J Cancer Prev 11(6):1523\u20131527","journal-title":"Asian Pac J Cancer Prev"},{"key":"6956_CR15","first-page":"145","volume":"9","author":"N Salihah","year":"2016","unstructured":"Salihah N, Mazlan N, Lua PL (2016) Chemotherapy-induced nausea and vomiting: exploring patients\u2019 subjective experience. J Multidiscip Healthc 9:145\u2013151","journal-title":"J Multidiscip Healthc"},{"issue":"3","key":"6956_CR16","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00520-018-4400-1","volume":"27","author":"S Chanthawong","year":"2019","unstructured":"Chanthawong S, Lim YH, Subongkot S, Chan A, Andalusia R, Ahmad Bustamam RS et al (2019) Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study. Support Care Cancer 27(3):1109\u20131119","journal-title":"Support Care Cancer"},{"key":"6956_CR17","doi-asserted-by":"publisher","first-page":"vi128","DOI":"10.1093\/annonc\/mdz343.046","volume":"30","author":"EIBM Mahidin","year":"2019","unstructured":"Mahidin EIBM, Ishak WZBW (2019) P1\u2013218 - Chemotherapy induced nausea and vomiting and quality of life of patients on moderate and highly emetogenic chemotherapy. Ann Oncol 30:vi128","journal-title":"Ann Oncol"},{"issue":"1","key":"6956_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00520-014-2372-3","volume":"23","author":"S Yu","year":"2015","unstructured":"Yu S, Burke TA, Chan A, Kim HK, Hsieh RK, Hu X et al (2015) Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy\u2013a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines. Support Care Cancer 23(1):273\u2013282","journal-title":"Support Care Cancer"},{"issue":"Suppl 1","key":"6956_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00520-018-4131-3","volume":"26","author":"M Aapro","year":"2018","unstructured":"Aapro M (2018) CINV: still troubling patients after all these years. Support Care Cancer 26(Suppl 1):5\u20139","journal-title":"Support Care Cancer"},{"key":"6956_CR20","unstructured":"US Department of Health and Human Services NIoH, National Cancer Institute, editor. Common terminology criteriafor adverse events (CTCAE) Version 5. 2017."},{"issue":"3","key":"6956_CR21","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1159\/000503095","volume":"12","author":"F Azam","year":"2019","unstructured":"Azam F, Latif MF, Farooq A, Tirmazy SH, AlShahrani S, Bashir S et al (2019) Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals. Case Rep Oncol 12(3):728\u2013736","journal-title":"Case Rep Oncol"},{"issue":"6","key":"6956_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"6956_CR23","unstructured":"Malaysia Ministry of Health Systemic Protocol for Chemotherapy. 3 ed2016."},{"issue":"6","key":"6956_CR24","doi-asserted-by":"publisher","first-page":"e1073","DOI":"10.1002\/onco.13716","volume":"26","author":"M Aapro","year":"2021","unstructured":"Aapro M, Scott\u00e9 F, Escobar Y, Celio L, Berman R, Franceschetti A et al (2021) Practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data. Oncologist 26(6):e1073\u2013e1082","journal-title":"Oncologist"},{"issue":"5","key":"6956_CR25","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","volume":"20","author":"K Tamura","year":"2015","unstructured":"Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H et al (2015) Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol 20(5):855\u2013865","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"6956_CR26","doi-asserted-by":"publisher","first-page":"883","DOI":"10.6004\/jnccn.2017.0117","volume":"15","author":"MJ Berger","year":"2017","unstructured":"Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ et al (2017) NCCN guidelines insights: antiemesis, Version 2.2017. J Natl Compr Canc Netw 15(7):883\u201393","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"6956_CR27","doi-asserted-by":"publisher","first-page":"334","DOI":"10.4103\/ijmpo.ijmpo_116_17","volume":"38","author":"G Baburaj","year":"2017","unstructured":"Baburaj G, Abraham AM, George L, Shetty V, Thempalangad RM, Rajesh KS et al (2017) A study on utilization and evaluation of antiemetics in chemotherapy-induced nausea and vomiting. Indian J Med Paediatr Oncol 38(3):334\u2013339","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"5","key":"6956_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.21037\/cco-20-160","volume":"9","author":"Y Yang","year":"2020","unstructured":"Yang Y, Yang N, Wu L, Ouyang Q, Fang J, Li J et al (2020) Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China. Chin Clin Oncol 9(5):68","journal-title":"Chin Clin Oncol"},{"issue":"4","key":"6956_CR29","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.7314\/APJCP.2016.17.4.1661","volume":"17","author":"DM Yuan","year":"2016","unstructured":"Yuan DM, Li Q, Zhang Q, Xiao XW, Yao YW, Zhang Y et al (2016) Efficacy and safety of neurokinin-1 receptor antagonists for prevention of chemotherapy-induced nausea and vomiting: systematic review and meta-analysis of randomized controlled trials. Asian Pac J Cancer Prev 17(4):1661\u20131675","journal-title":"Asian Pac J Cancer Prev"},{"issue":"9","key":"6956_CR30","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1248\/bpb.b17-00318","volume":"40","author":"M Uchida","year":"2017","unstructured":"Uchida M, Mori Y, Nakamura T, Kato K, Kamezaki K, Takenaka K et al (2017) Comparison between antiemetic effects of palonosetron and granisetron on chemotherapy-induced nausea and vomiting in Japanese patients treated with R-CHOP. Biol Pharm Bull 40(9):1499\u20131505","journal-title":"Biol Pharm Bull"},{"issue":"9","key":"6956_CR31","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1007\/s00520-017-3679-7","volume":"25","author":"T Hayashi","year":"2017","unstructured":"Hayashi T, Shimokawa M, Miyoshi T, Toriyama Y, Yokota C, Taniguchi J et al (2017) A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting. Support Care Cancer 25(9):2707\u20132714","journal-title":"Support Care Cancer"},{"issue":"9","key":"6956_CR32","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/hed.23753","volume":"37","author":"A Chan","year":"2015","unstructured":"Chan A, Shwe M, Gan Y, Yap K, Chew L, Lim WT (2015) Trajectory and risk factors for chemotherapy-induced nausea and vomiting in Asian patients with head and neck cancer. Head Neck 37(9):1349\u20131357","journal-title":"Head Neck"},{"issue":"2","key":"6956_CR33","doi-asserted-by":"publisher","first-page":"168","DOI":"10.21147\/j.issn.1000-9604.2016.02.04","volume":"28","author":"X Zong","year":"2016","unstructured":"Zong X, Zhang J, Ji X, Gao J, Ji J (2016) Patterns of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting in China. Chin J Cancer Res 28(2):168\u2013179","journal-title":"Chin J Cancer Res"},{"issue":"2","key":"6956_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10147-016-1069-7","volume":"22","author":"K Tamura","year":"2017","unstructured":"Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H et al (2017) Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan. Int J Clin Oncol 22(2):405\u2013412","journal-title":"Int J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06956-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-06956-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06956-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T06:56:47Z","timestamp":1651042607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-06956-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["6956"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-06956-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]},"assertion":[{"value":"10 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was obtained from the Medical Research and Ethics Committee (MREC), Ministry of Health Malaysia (NMRR-20\u20132988-57474), and the study center permission was obtained from the Director of the National Cancer Institute, Ministry of Health Malaysia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}